Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified in the protocol.”In the company’s words, NCT05797610 on ClinicalTrials.gov
- Tested for
- Primary IgA Nephropathy
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy, safety, \& pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.”In the company’s words, NCT05797610 on ClinicalTrials.gov
Other drugs for Primary IgA Nephropathy
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up1
- 25 May 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 25 May 2028 | A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026